Every 10-Q that Neumora Therapeutics, Inc. (NMRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NMRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NMRA filings page.
Neumora Therapeutics, Inc. reported continuing losses and liquidity pressure for the quarter ended June 30, 2026. Net loss was $43.1 million for the quarter and $96.5 million for the first half of 2026, driven by research and development expenses of $67.9 million and general and administrative expenses of $27.2 million over six months.
Cash and cash equivalents were $116.8 million at June 30, 2026, down from $182.5 million at year-end, with $85.9 million used in operating activities in the first half. Management concluded that existing cash will not fund operating plans for at least 12 months, raising substantial doubt about the company’s ability to continue as a going concern. Neumora discontinued development of navacaprant in major depressive disorder following Phase 3 results and is now focusing on NMRA-511 for agitation in Alzheimer’s disease, NMRA-898 for schizophrenia, and NMRA-215 for obesity and cardiovascular risk. The company has a $60.0 million term loan outstanding, interest-only through April 2029, with a minimum liquidity covenant effective July 1, 2026 and a final maturity in May 2029.
Neumora Therapeutics, Inc. reported a net loss of $53.5M for the quarter ended March 31, 2026, narrower than the prior-year period. Operating expenses fell to $52.9M as both research and development and general and administrative costs declined.
The company ended the quarter with $147.1M in cash and cash equivalents and believes this will fund operations for at least 12 months from issuance of the statements. Net cash used in operating activities was $46.4M, partly offset by $10.9M of proceeds from at-the-market stock sales.
Neumora remains a clinical-stage biotech with no product revenue, advancing multiple brain-focused programs. Its lead asset, navacaprant for major depressive disorder, is in Phase 3, with KOASTAL-2 and KOASTAL-3 topline data expected in the second quarter of 2026. Additional readouts for NMRA-511 and NMRA-898 are planned for the second half of 2026.
Neumora Therapeutics reported a Q3 2025 net loss of $56.8 million, with nine‑month net loss at $177.5 million. Operating expenses fell year over year as research and development declined to $40.5 million from $60.6 million, and general and administrative to $12.2 million from $16.0 million. The company recorded $5.0 million of acquired in‑process R&D tied to its Vanderbilt M4 program.
Cash, cash equivalents and marketable securities totaled $171.5 million as of September 30, 2025. Neumora believes this will fund operations for at least the next 12 months. In May, it drew $20.0 million from a term loan facility with K2 HealthVentures (up to $125.0 million across tranches) at a minimum rate of 10.45%, and subsequently borrowed an additional $40.0 million after quarter‑end.
The pipeline includes a Phase 3 program for navacaprant in major depressive disorder and a Phase 1b study for NMRA‑511 in agitation due to Alzheimer’s disease, with early‑stage M4 PAM candidates advancing. Shares outstanding were 167,089,114 as of November 1, 2025.